Personalized Treatment is Better than one Treatment Fits All in the Management of Patients with mCRC: A Consensus Statement | Zendy

Şuayib Yalçın | Zendy; Diaeddine Trad | Zendy; Yasser Abdel Kader | Zendy; H. Halawani | Zendy; Osman Gökhan Demir | Zendy; Riaz Mall | Zendy; Andrey Meshcheryakov | Zendy; Fadi Nasr | Zendy; Adam Nosworthy | Zendy; Dmitry Osinsky | Zendy; Assel Tumanova | Zendy; Serdar Turhal | Zendy; Sabine Tejpar | Zendy; ClausHenning Köhne | Zendy

Open Access

Personalized Treatment is Better than one Treatment Fits All in the Management of Patients with mCRC: A Consensus Statement

Author(s) -

Şuayib Yalçın,

Diaeddine Trad,

Yasser Abdel Kader,

H. Halawani,

Osman Gökhan Demir,

Riaz Mall,

Andrey Meshcheryakov,

Fadi Nasr,

Adam Nosworthy,

Dmitry Osinsky,

Assel Tumanova,

Serdar Turhal,

Sabine Tejpar,

ClausHenning Köhne

Publication year - 2014

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon.14.203

Subject(s) - medicine , bevacizumab , panitumumab , cetuximab , oncology , colorectal cancer , targeted therapy , chemotherapy , cancer

The VEGF- (bevacizumab) and EGFR- (cetuximab and panitumumab) targeting monoclonal antibodies have become integral components of the first-line treatment strategies for patients with metastatic colorectal cancer (mCRC). Increasingly combination chemotherapy, with or without a targeted agent, is being used to facilitate curative liver resection and improve survival rates in patients with initially unresectable but potentially resectable mCRC. Currently, the only selective marker for the treatment of patients with mCRC is tumor RAS mutational status. BRAF status is a strong prognostic indicator. Medical and clinical oncologists from Central Asia, Russia, the Middle East, Africa and Turkey reviewed data for the use of targeted agents in the treatment of patients with mCRC and have formed recommendations for the biological of choice first-line for patients with mCRC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research